| Loss of p53 triggers WNT-dependent systemic inflammation to drive breast cancer metastasis MD Wellenstein, SB Coffelt, DEM Duits, MH van Miltenburg, M Slagter, ... Nature 572 (7770), 538-542, 2019 | 453 | 2019 |
| Structure of the homodimeric androgen receptor ligand-binding domain M Nadal, S Prekovic, N Gallastegui, C Helsen, M Abella, K Zielinska, ... Nature communications 8 (1), 14388, 2017 | 201 | 2017 |
| Androgen receptor antagonists for prostate cancer therapy C Helsen, T Van den Broeck, A Voet, S Prekovic, H Van Poppel, S Joniau, ... Endocrine-related cancer 21 (4), T105-T118, 2014 | 173 | 2014 |
| Emerging mechanisms of enzalutamide resistance in prostate cancer F Claessens, C Helsen, S Prekovic, T Van den Broeck, L Spans, ... Nature reviews urology 11 (12), 712-716, 2014 | 155 | 2014 |
| The effect of F877L and T878A mutations on androgen receptor response to enzalutamide S Prekovic, ME van Royen, ARD Voet, B Geverts, R Houtman, D Melchers, ... Molecular cancer therapeutics 15 (7), 1702-1712, 2016 | 115 | 2016 |
| Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse S Taavitsainen, N Engedal, S Cao, F Handle, A Erickson, S Prekovic, ... Nature communications 12 (1), 5307, 2021 | 92 | 2021 |
| The role of single nucleotide polymorphisms in predicting prostate cancer risk and therapeutic decision making T Van den Broeck, S Joniau, L Clinckemalie, C Helsen, S Prekovic, ... BioMed research international 2014 (1), 627510, 2014 | 78 | 2014 |
| Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond S Linder, HG van der Poel, AM Bergman, W Zwart, S Prekovic Endocrine-related cancer 26 (1), R31-R52, 2019 | 73 | 2019 |
| Drivers of AR indifferent anti-androgen resistance in prostate cancer cells F Handle, S Prekovic, C Helsen, T Van den Broeck, E Smeets, L Moris, ... Scientific reports 9 (1), 13786, 2019 | 64 | 2019 |
| Comparative genomic and transcriptomic analyses of LNCaP and C4-2B prostate cancer cell lines L Spans, C Helsen, L Clinckemalie, T Van den Broeck, S Prekovic, ... PloS one 9 (2), e90002, 2014 | 59 | 2014 |
| Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer S Prekovic, K Schuurman, I Mayayo-Peralta, AG Manjón, M Buijs, S Yavuz, ... Nature Communications 12 (1), 4360, 2021 | 53 | 2021 |
| Duality of glucocorticoid action in cancer: tumor-suppressor or oncogene? I Mayayo-Peralta, W Zwart, S Prekovic Endocrine-related cancer 28 (6), R157-R171, 2021 | 47 | 2021 |
| Identification of mineralocorticoid receptor target genes in the mouse hippocampus LTCM van Weert, JC Buurstede, HCM Sips, S Vettorazzi, IM Mol, ... Journal of Neuroendocrinology 31 (8), e12735, 2019 | 39 | 2019 |
| Genomic and epigenomic analysis of high-risk prostate cancer reveals changes in hydroxymethylation and TET1 L Spans, T Van den Broeck, E Smeets, S Prekovic, B Thienpont, ... Oncotarget 7 (17), 24326, 2016 | 39 | 2016 |
| Molecular underpinnings of enzalutamide resistance S Prekovic, T Van den Broeck, S Linder, ME van Royen, AB Houtsmuller, ... Endocrine-related cancer 25 (11), R545-R557, 2018 | 38 | 2018 |
| TLE3 loss confers AR inhibitor resistance by facilitating GR-mediated human prostate cancer cell growth SAL Palit, D Vis, S Stelloo, C Lieftink, S Prekovic, E Bekers, I Hofland, ... Elife 8, e47430, 2019 | 35 | 2019 |
| The androgen receptor depends on ligand‐binding domain dimerization for transcriptional activation S El Kharraz, V Dubois, ME van Royen, AB Houtsmuller, E Pavlova, ... EMBO reports 22 (12), e52764, 2021 | 32 | 2021 |
| Androgen and glucocorticoid receptor direct distinct transcriptional programs by receptor-specific and shared DNA binding sites M Kulik, M Bothe, G Kibar, A Fuchs, S Schöne, S Prekovic, ... Nucleic acids research 49 (7), 3856-3875, 2021 | 29 | 2021 |
| Endonuclease FEN1 Coregulates ERα activity and provides a novel drug Interface in Tamoxifen-resistant breast Cancer KD Flach, M Periyasamy, A Jadhav, D Dorjsuren, JC Siefert, TE Hickey, ... Cancer research 80 (10), 1914-1926, 2020 | 25 | 2020 |
| A CRISPR-Cas9 screen identifies essential CTCF anchor sites for estrogen receptor-driven breast cancer cell proliferation G Korkmaz, Z Manber, R Lopes, S Prekovic, K Schuurman, Y Kim, ... Nucleic Acids Research 47 (18), 9557-9572, 2019 | 23 | 2019 |
Frank ClaessensKU LeuvenVerified email at med.kuleuven.be